Background: Right heart failure (RHF) is a well-known consequence of left ventricular assist device (LVAD) placement, and has been linked to negative surgical outcomes. However, little is known regarding risk factors associated with RHF. This article delineates pre-and intra-operative risk factors for RHF following LVAD implantation and demonstrates the effect of RHF severity on key surgical outcomes. Methods: We performed a retrospective analysis of consecutive LVAD patients treated at our center between 2008 and 2016. RHF was categorized using the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definition of none/mild, moderate, severe, and acute-severe. We constructed a predictive model using multivariable logistic regression and performed a competing risks analysis for survival stratified by RHF severity.
Introduction
Right heart failure (RHF) is a common complication following left ventricular assist device (LVAD) placement, with prevalence reports ranging between 10-50% of patients (1) (2) (3) (4) . Left ventricular (LV) contractile forces contribute 20-40% of right ventricular (RV) output (4) , and the hemodynamic effects of LVAD placement can have deleterious effects on native RV function (5) . Modifying RV physiology by altering preload and afterload of the LV, optimizing RV protection, and minimizing blood transfusions intra-operatively have been shown to limit both RHF occurrence and progression. RHF following
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Predictors and impact of right heart failure severity following left ventricular assist device implantation LVAD implantation, even when treated medically and with right ventricular assist device (RVAD) support, has been associated with increased hospital length of stay (LOS) and decreased survival of patients, even after successful cardiac transplantation (1, (6) (7) (8) (9) . Although multiple risk factors for predicting RHF following LVAD implantation are available (10) (11) (12) , the optimal method to anticipate this complication remains uncertain (13) . Furthermore, the methods used for the diagnosis and categorization of RHF following LVAD are debated. Most definitions are based on a combination of hemodynamic derangement indicators and the duration of postoperative inotropes (1) . This article aims to further delineate the contributing preoperative and intraoperative risk factors for RHF development following LVAD implantation and to demonstrate the effect of RHF on patients' postoperative outcomes.
Methods

Clinical
We performed a retrospective analysis using a prospectively maintained database of consecutive LVAD patients implanted between 2008 and 2016 at the Baylor University Medical Center, Dallas, Texas. In this cohort, RHF was categorized using the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) inotropebased definition (14) of none, mild (≤7 days on inotropes), moderate (8-14 days), severe (>14 days), and acutesevere (requiring RVAD). Preoperative characteristics evaluated included gender, age, body mass index (BMI), INTERMACS profile, and other medical comorbidities ( Table 1) . Perioperative data included cross-clamp use, cardiopulmonary bypass (CPB) time, nadir hematocrit, and volume removed via ultrafiltration during bypass. The primary outcome was severity of RHF. Other post-operative variables ranged from infectious processes, hemodynamic values, device problems, and death at 1 year. The clinical course for each patient was followed for 1 year following LVAD implantation. The protocol for data collection was approved by the Institutional Review Board of Baylor University Medical Center Dallas (IRB File #011-274), and informed consent was waived.
Statistical analysis
The Kruskal Wallis test and the Cochran-Armitage trend test (or Fisher's Exact test, as needed) were used to examine differences in patient characteristics and surgical outcomes across the categories of RHF. We built a multivariable logistic regression model via stepwise selection, in which we considered all variables having a significant association in univariate analyses for the dichotomized outcome of moderate or worse RHF compared to no RHF (moderate, severe, and acute severe categories were combined for this analysis due to limited sample size; there were no instances of mild RHF). We performed a competing risks analysis using the Fine and Gray method to assess the effect of RHF severity on survival, while accounting for the competing risk of transplantation (15) . For simplicity, we use the terms 'survival' and 'mortality' in this manuscript when we truly mean transplant-free survival and transplant-free mortality. Continuous variables are reported as median [25 th percentile, 75 th percentile]. Categorical variables are reported as frequencies and percentages. Statistical significance is defined as a P value <0.05. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
There were 202 subjects included in this analysis, 52 (26%) of whom developed a moderate or worse form of RHF (22 moderate, 14 severe, 16 acute severe). Approximately 90% of the subjects received a HeartMate 2 device. Age, comorbidities, and medication use were similar across RHF severity; however, gender, serum creatinine, pre-operative LOS, Model for End-Stage Liver Disease (MELD) scores, HeartMate Risk scores, and INTERMACS profiles differed significantly ( Table 1) . One hundred twenty-eight (85.3%) of those without RHF were male, compared to only 11 (68.8%) of those with acute-severe RHF. The median pre-operative LOS more than doubled as RHF severity increased (5.5 to 11.5 days, P=0.04). There were 10 (62.5%) INTERMACSprofile-1 patients in the acute-severe RHF group compared to 16 (10.7%), 7 (31.8%), and 1 (7.1%) patients in the no RHF, moderate, and severe groups, respectively (P<0.001). Significant differences were also observed in intra-operative variables such as CPB time and nadir hematocrit. The median CPB time ranged from 74 to 159 minutes as RHF severity worsened. Nadir hematocrit decreased from 27% to 24% as RHF severity worsened.
Due to the limited number of individuals who developed moderate or worse forms of RHF, we were unable to build a multivariable model to classify RHF severity; however, we combined the categories of moderate, severe, and acute severe into one category and compared it to those without (Figure 1) .
Postoperative LOS differed significantly across the RHF severity groups, with the shortest median stay (13 days) for those who did not develop RHF and the longest median stay (29.5 days) for those who developed acute-severe RHF ( Table 2 ). The following postsurgical outcomes also differed significantly by RHF severity: incidence of stage 2/3 acute kidney injury (AKI), as defined by Kidney Disease Improving Global Outcomes (KDIGO) guidelines (16) (ranging from 26% in the no RHF group to 57% in the severe group, P=0.002), respiratory failure (12.7% to 93.8%, P<0.001), stroke (0% to 31.8%, P=0.002), exploratory operation for bleeding (10.7% to 43.8%, P=0.003), and vasoplegia severity (P<0.001) ( Table 2 ). The rates of mortality at 30 days (range, 2.0-25%; P=0.001) and 1 year (19.3-64.3%, P=0.002) increased with RHF severity. When considered as a time-toevent outcome, those who developed acute-severe RHF were at 5.4 (95% CI: 2.5-11.8) times the risk of 1-year mortality when compared to those who did not have RHF (Figure 2) . Similarly, those with severe RHF were at 3.2 (95% CI: 1.2-8.6) times the risk, and those with moderate RHF were at 2.1 (95% CI: 0.8-5.2) times the risk of 1-year mortality. Although there was a significant difference in preoperative serum creatinine across the RHF severity groups, preoperative estimated glomerular filtration rates, which take into account gender, age, and race, demonstrated no such difference. Intraoperatively, extended CPB time and decreased hematocrit, which has potential to necessitate blood transfusions (6) , were found to be associated with increased RHF severity. Increasing rates of concomitant procedures and ECMO across RHF severity may partially explain the longer CPB times as RHF severity worsened. Following LVAD placement, RHF severity was significantly related to postoperative LOS, AKI, respiratory failure, and stroke. Finally, the presence and degree of RHF negatively impacted 30-day and 1-year survival rates post-LVAD implantation.
Discussion
Approximately 1 in 4 patients in this cohort developed
Our results confirm prior studies regarding the lack of a relation between RHF and patient age (6, 7, 10) . Our work also confirms that females may be at increased risk for RHF after LVAD placement (8, 17) . Further, our work reiterates the link between RHF and preoperative serum creatinine (12) , elevated BMI (11) , and longer preoperative (10) and postoperative LOS (7) . A prior study demonstrated that the need for RVAD placement during the initial LVAD procedure significantly increased the risk of RV dysfunction and RHF; similarly, longer CPB time required for LVAD implantation was linked to worsening RHF in our study (1) . Our finding of decreased perioperative hematocrit in more severe RHF is reflective of a prior study that found lower nadir hematocrit to be significantly associated with increased mortality in patients undergoing CPB (18) . It also aligns with another study in which the need for blood transfusions was related to RHF severity (6) . The decreased survival rates with increased RHF severity has also been previously documented (6, 8, 10, 11) .
Patients who develop RHF in the postoperative setting are at risk for developing multi-organ dysfunction, especially of the respiratory and renal systems. Our study demonstrated similar results. These conditions, along with postoperative mortality, are associated with the severity of RHF, further stressing the importance of volume, mechanical device, and natural cardiac optimization to limit RHF occurrence and progression. Awareness of RHF development and its consequences has increased over the years and novel strategies have been implemented in attempts to prevent its occurrence and limit its progression. Close echocardiographic ventricular monitoring with careful LVAD flow dynamic adjustments, non-pulsatile LVAD designs, and intra-operative RVAD placement prior to RHF development are a few innovations proven to reduce RHF based on clinical experience and research (1, 3) . Others include methods to decrease pulmonary hypertension, such as the use of nitric oxide gas and PDE-5 inhibitors perioperatively, and improve RV support, such as using the percutaneous RV Impella device (1, 19, 20) .
RHF following LVAD implantation is an unfortunate complication with significantly negative implications for surgical outcomes. This increased risk of postoperative complications, including death, causes an urgent need for improved RHF risk stratification for LVAD candidates. Furthermore, the sensitivity to hemodynamic alterations exhibited in these patients cannot be overemphasized. A delicate balance of volume status, natural heart function, and mechanical function must be maintained, which is especially crucial immediately following the operation. Specialized patient care will be better directed as more is learned regarding the characteristics of patients who develop RHF. For example, our findings indicate that LVAD patients with higher BMI and pre-existing renal dysfunction could be considered at increased risk and may require additional monitoring in both the pre and post-operative settings. Our work also indicates that CPB time and volume shifts intraoperatively should be kept at a minimum, when clinically possible.
